Revenue: As of FY2026 Q1, the actual value is USD 761.7 M, beating the estimate of USD 730.1 M.EPS: As of FY2026 Q1, the actual value is USD 1.3, beating the estimate of USD 1.1618.EBIT: As of FY2026 Q1, the actual value is USD 131.9 M.<h4>Segment Revenue</h4><ul><li>U.S. Omnipod Products: Revenue increased by 28.3% to $515.6 million for the three months ended March 31, 2026, compared to $401.7 million for the same period in 2025. </li><li>International Omnipod Products: Revenue increased by 59.4% to $242.9 million for the three months ended March 31, 2026, compared to $152.3 million for the prior year period. Excluding a 14.2% favorable currency exchange impact, the constant currency increase was 45.2%. </li><li>Drug Delivery: Revenue decreased significantly to $3.3 million for the three months ended March 31, 2026, from $14.9 million in the prior year period. </li></ul><h4>Operational Metrics</h4><ul><li>Cost of Revenue: Increased by 45.5% to $232.7 million for the three months ended March 31, 2026, up from $159.9 million in the prior year period. </li><li>Gross Margin: Decreased to 69.5% for the three months ended March 31, 2026, from 71.9% in the prior year period. </li><li>Research and Development Expenses: Increased by 50.6% to $89.7 million for the three months ended March 31, 2026, compared to $59.6 million in the prior year. </li><li>Selling, General and Administrative Expenses: Increased by 21.7% to $317.2 million for the three months ended March 31, 2026, from $260.7 million in the prior year. </li><li>Operating Income: Rose to $122.1 million for the three months ended March 31, 2026, from $88.8 million in the prior year period. </li><li>Net Income: Increased to $91.1 million for the three months ended March 31, 2026, from $35.4 million in the prior year period. </li><li>Interest Expense: Increased to $14.7 million for the three months ended March 31, 2026, from $9.2 million in the prior year. </li><li>Interest Income: Decreased to $4.9 million for the three months ended March 31, 2026, from $10.3 million in the prior year. </li><li>Loss on Extinguishment of Debt: Insulet Corporation recognized no loss in 2026, compared to - $39.5 million loss in the prior year. </li><li>Income Tax Expense: Was $21.9 million for the three months ended March 31, 2026, compared to $12.7 million in the prior year, with an effective tax rate of 19.4% and 26.4% respectively. </li><li>Adjusted EBITDA: Increased to $181.7 million for the three months ended March 31, 2026, from $133.9 million in the prior year period. </li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by Operating Activities: Was $113.8 million for the three months ended March 31, 2026, up from $63.8 million in the prior year period. </li><li>Net Cash Used in Investing Activities: Was - $27.7 million for the three months ended March 31, 2026, compared to - $15.6 million in the prior year. </li><li>Net Cash Used in Financing Activities: Was - $319.9 million for the three months ended March 31, 2026, a shift from $277.7 million provided in the prior year period. </li><li>Free Cash Flow: Increased to $89.5 million for the three months ended March 31, 2026, from $51.6 million in the prior year. </li></ul><h4>Unique Metrics</h4><ul><li>Product Warranty Liability: Stood at $24.7 million as of March 31, 2026, up from $16.1 million as of March 31, 2025. </li><li>Voluntary Medical Device Correction: Insulet Corporation accrued an estimated liability of $11.7 million related to a voluntary medical device correction for Omnipod 5 Pods during the first quarter of 2026. </li><li>Capital Expenditures: Totaled $24.3 million for the three months ended March 31, 2026, compared to $12.3 million in the prior year. </li><li>Share Repurchase Program: Insulet Corporation repurchased approximately 1.25 million shares of common stock for $300.0 million during the three months ended March 31, 2026. </li><li>Total Debt, Net: Was $948.1 million as of March 31, 2026, compared to $949.2 million as of December 31, 2025. </li><li>Debt-to-Total Capital Ratio: Increased to 42% as of March 31, 2026, from 39% as of December 31, 2025. </li><li>Net Debt-to-Total Capital Ratio: Increased to 21% as of March 31, 2026, from 9% as of December 31, 2025. </li></ul><h4>Future Outlook and Strategy</h4>Insulet Corporation anticipates strong U.S. revenue growth for the full year 2026, driven by its recurring revenue model and continued volume growth of Omnipod 5. International Omnipod revenue is also projected to increase due to new customers and higher average selling prices from Omnipod 5 conversions. The company expects net interest expense for the full year 2026 to increase to approximately $40 million due to lower interest income.

Insulet | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 761.7 M